Hap Trading, LLC Geron Corp Put Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 14, 2023	BUY	$2.03 - $2.42 $22,532 - $26,862	11,100 Added 103.74%	21,800 $6,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $17,869 - $31,458	10,700 New	10,700 $5,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $4,148 - $5,848	3,400 Added 31.48%	14,200 $3,000
Q1 2021 May 14, 2021	SELL	$1.52 - $2.1 $12,768 - $17,640	-8,400 Reduced 43.75%	10,800 $6,000
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $1,705 - $2,255	1,100 Added 6.08%	19,200 $9,000
Q3 2020 Nov 13, 2020	BUY	$1.59 - $2.19 $636 - $876	400 Added 2.26%	18,100 $7,000
Q2 2020 Aug 10, 2020	BUY	$1.05 - $2.18 $1,260 - $2,616	1,200 Added 7.27%	17,700 $8,000
Q1 2020 May 08, 2020	SELL	$0.89 - $1.49 $356 - $596	-400 Reduced 2.37%	16,500 $17,000
Q4 2019 Feb 11, 2020	BUY	$1.27 - $1.54 $508 - $616	400 Added 2.42%	16,900 $15,000
Q3 2019 Nov 12, 2019	SELL	$1.15 - $1.59 $11,040 - $15,264	-9,600 Reduced 36.78%	16,500 $15,000
Q3 2018 Nov 09, 2018	BUY	$1.76 - $6.38 $45,936 - $166,518	26,100 New	26,100 $57,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.